ReviewDrugs & aging2014
Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects.
Review in Drugs & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Chronic Pain in Elderly Patients: Pathophysiology, Pharmacologic and Non-Pharmacologic Therapies, and Interventional Management.Clinical pharmacology : advances and applications · 2026Review
- Pharmacological Pain Treatment in Older Persons.Drugs & aging · 2024Review
- Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study.The Lancet regional health. Europe · 2023Article
- Topical Lidocaine for Chronic Pain Treatment.Drug design, development and therapy · 2021Review
- Managing Pain in the Older Cancer Patient.Current oncology reports · 2019Review
- Localized neuropathic pain: an expert consensus on local treatments.Drug design, development and therapy · 2017Review
- An Algorithm for Neuropathic Pain Management in Older People.Drugs & aging · 2016Article
- Pain in the Elderly.Current pain and headache reports · 2016Review
- Observational
- Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects.Drugs & aging · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-herpetic neuralgia is a painful condition and its prevalence increases with age. It is a burden for older patients and the association of age-related pharmacokinetic and pharmacodynamic changes, high co-morbidity and polypharmacy leads to the risk of adverse drug reactions and interactions. This type of neuropathic pain is particularly difficult to treat and guidelines recommend the use of gabapentinoids and some antidepressants, the utility of which may be hampered by adverse effects such as sedation, dizziness and impaired age-related renal function. Re-formulations of antiepileptics (anticonvulsants) are being developed and/or marketed and suggest interesting innovative profiles with improved bioavailability, low drug-drug interactions and better tolerability that need to be confirmed in future studies. However, there are no new antiepileptics being developed for post-herpetic neuralgia, and prospective studies specifically focused on the older population are still missing, while this age group is particularly at risk of developing shingles and chronic neuropathic pain with a deleterious impact on quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.